If you think you have missed your eye or not quite dropped the product in the correct part of your eye, insert another drop

Medicines which are appropriate for initiation and ongoing prescribing in both primary and secondary care. Sodium Hyaluronate(e.g. Hyabak, Hylo-tear, Hylo-Forte, Hy-Opti, Oxyal, Clinitas, Vizulize, Evolve HA, VisuXL) Each pre-filled syringe contains 3.6mg in 0.09mL solution- this contains a usable amount to deliver a dose of 2mg in 0.05ml i.e. treatment for 1 eye. If the patient is having 2 eyes treated, 2syringes must be used) Evolve Hypromellose Eye Drops is a lubricating eye drop indicated to provide relief arising from discomfort caused by dry eye sensations. Medicines suitable to be prescribed in primary care / general practice after specialist* recommendation or initiation.Do NOT drive or operate machines if you experience any visual disturbance after using the product, wait until this clears before driving or using machines. MHRA: Drug safety Update (January 2022): Brolucizumab (Beovu¥): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals

Secondary Careprescribing: Brand supplied will depend on availability. Evolve ® brand is a cost-effective option. Grey / Non-Formulary: Medicines, which the Nottinghamshire APC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. Evolve ®(preservative free) - reserved for patients unable to tolerate preservatives. Expiry of multi-dose bottle is 3 months after opening for the Evolve brand. Approved in accordance with MHRAEarly Access to Medicines Scheme to treat the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are currently not taking glucocorticoids. EAMS number 46555/0001.

No new patients to receive prescriptions in primary care. Patients already receiving Red Medicines in primary care should be handled on a case by case basis with the support of the Medicines Optimisation team. NUH only - Visual impairment in adults caused by macular oedema after branch retinal vein occlusion (BRVO) NICE TA409